Melatonin in Patients With Multiple Sclerosis (MS).

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

July 29, 2022

Study Completion Date

December 11, 2023

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

3 mg Melatonin

3 mg melatonin once each day

DRUG

5 mg Melatonin

5 mg Melatonin once each day

Trial Locations (1)

Providence MS Center, Portland

All Listed Sponsors

lead

Providence Health & Services

OTHER

NCT03498131 - Melatonin in Patients With Multiple Sclerosis (MS). | Biotech Hunter | Biotech Hunter